Teverelix

Summary

Teverelix is a long-acting GnRH antagonist peptide investigated primarily for prostate cancer and benign prostatic hyperplasia (BPH). Unlike GnRH agonists, it produces rapid castration-level testosterone suppression without the initial hormonal flare. It was developed as a depot formulation intended for infrequent dosing.

Mechanism of Action

Competitively blocks gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, suppressing release of LH and FSH, thereby rapidly reducing testosterone and estrogen levels without an initial testosterone surge (flare).

Routes of Administration

Goals & Uses

• Treatment of endometriosisGynecologyLow
• Prevention of premature LH surge in assisted reproductionReproductive MedicineLow
• Testosterone suppression in prostate cancerOncologyModerate
• Reduction of lower urinary tract symptoms in BPHUrologyModerate

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Known hypersensitivity to GnRH antagonists or any peptide excipientAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• Injection site reactionsLocalCommon
• Anaphylaxis / hypersensitivityImmunologicRare
• Decreased libidoSexual / EndocrineCommon
• Erectile dysfunctionSexual/ReproductiveCommon
• Hot flushesVasomotorCommon
• Bone mineral density reductionMusculoskeletalUncommon

Drug Interactions

• Antidiabetic agentsLow
• QT-prolonging agents (e.g., antiarrhythmics, antipsychotics)Moderate

Population Constraints

• Pediatric patientsAgeAbsolute
• Patients with pre-existing osteoporosisMusculoskeletalRelative
• Patients with cardiovascular diseaseComorbidityRelative
• Women of childbearing potentialReproductiveRelative

Regulatory Status

• European UnionInvestigationalInvestigated under EMA oversight in clinical trials; no marketing authorization granted. Ardana Bioscience (Edinburgh, UK) conducted European trials.
• United StatesInvestigationalTeverelix was studied in clinical trials but never received FDA approval. Development was discontinued.
• United KingdomInvestigationalNo MHRA approval; studied in UK-based clinical programs prior to Ardana's dissolution.

Teverelix has not received regulatory approval from the FDA, EMA, or other major agencies. Clinical development was pursued by Ardana Bioscience and later other entities; development was halted or suspended. No approved indication exists in any major jurisdiction.

Evidence & Sources

No sources recorded yet.